The SURPASS-4 trial compared different doses of tirzepatide (5, 10 or 15 mg) with insulin glargine in 1,995 adults (average age 63.6 years; 38% female) with T2D who were at increased risk for ...

The SURPASS 1 through 5 studies were phase 3 clinical trials in which researchers compared the efficacy of 5, 10, or 15 mg tirzepatide with placebo, 1 mg semaglutide, insulin degludec, or insulin ...

Previously, the SURPASS-5 trial compared tirzepatide or placebo plus insulin glargine. Similarly, all three doses of tirzepatide -- 5, 10, or 15 mg -- yielded significantly greater HbA1c ...

"Results from SURPASS-SWITCH suggest that escalating ... 40 (estimated treatment difference -18.4 mg/dL, 95% CI -25.5 to -11.2). Tirzepatide switchers also had a 5.1 cm greater reduction in ...

"The analysis shows that in the SURPASS-4 trial, approximately 80% of individuals who were treated with tirzepatide and who reached an A1c of 6.5% or weight loss > 10% at 52 weeks retained those ...

their detection and performance bias were high due to the SURPASS studies being open-label, non-blinded studies. Meta-analysis results revealed that Tirzepatide (all three doses – 5, 10 ...

Doses range from 2.5 milligrams (mg ... have been found across the series of Surpass trials that studied tirzepatide in people with type 2 diabetes, according to an analysis of studies published ...

3.9 The committee noted that the marketing authorisation for tirzepatide states that it should be titrated as needed to recommended maintenance doses of 5 mg, 10 mg or 15 mg. In contrast, in the ...

To assess the effect of tirzepatide on metabolic syndrome prevalence, researchers conducted a post hoc analysis of SURPASS 1-5. Adults with type 2 diabetes (N=5219) were randomly assigned to ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their ...